Caroline Koedoot

  • Citations Per Year
Learn More
In palliative cancer treatment, the choice between palliative chemotherapy and best supportive care may be difficult. In the decision-making process, giving information as well as patients' values and preferences become important issues. Patients, however, may have a treatment preference before they even meet their medical oncologist. An insight into the(More)
PURPOSE To determine the preferences of oncologists for palliative chemotherapy or watchful waiting and the factors considered important to that preference. METHODS Sixteen vignettes (paper case descriptions), varying on eight patient and treatment characteristics, were designed to assess the oncologists' preferences. Their strength of preference was(More)
Although persistent developmental stuttering is known to affect daily living, just how great the impact is remains unclear. Furthermore, little is known about the underlying mechanisms which lead to a diminished quality of life (QoL). The primary objective of this study is to explore to what extent QoL is impaired in adults who stutter (AWS). In addition,(More)
This study aimed to determine the content and the amount of information given by medical oncologists when proposing palliative chemotherapy and whether this information given is influenced by patient or physician background characteristics. In a prospective study, 95 patients with incurable cancer were interviewed before they consulted their medical(More)
UNLABELLED The Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-A; Yaruss & Quesal, 2006, 2010) is a patient-reported outcome measure that was designed to provide a comprehensive assessment of "the experience of the stuttering disorder from the perspective of individuals who stutter" (Yaruss & Quesal, 2006, p. 90). This paper(More)
The discomfort and benefits of a medical treatment may be appreciated differently by different patients. This is one of the reasons why patients should be informed thoroughly and included in the decision-making about treatment. The obligation to inform was laid down in 1995 in the Decree on the Medical Contract. In a case of metastasized cancer of the(More)
  • 1